Patients and Methods:
During 4 years period of study 135 patients of early-onset ataxia were registered that 25 patients with treatable ataxia were evaluated during the last 2-4 years, from 2017 to 2021. After detailed clinical and laboratory evaluation and exclusion of acquired causes of ataxia, they were subjected to whole-exome sequencing (WES) followed by confirmation of sequence variants using Sanger sequencing. Then, patients who had treatable ataxia(2) with genetic confirmation entered our study. We administered the drug of choice depending on the type of ataxia and followed patients regularly. Then we recorded related data including age, sex, onset of ataxia, additional features, age of definite diagnosis, genetic testing results, type of treatment, and outcome.